Baseline characteristics of a subgroup of 214 patients from the OPTIMAAL study divided into quartiles of mid-regional pro-adrenomedullin (MR-proADM)
| Variable | Total (N=214) | MR-proADM <0.64 (N=54) | MR-proADM 0.64–0.82 (N=53) | MR-proADM 0.83–1.02 (N=54) | MR-proADM >1.02 (N=53) | p Value for trend |
| Mean (±SD) age | 68 (10) | 63 (9) | 65 (9) | 69 (10) | 75 (11) | <0.001 |
| Female (%) | 64 (30) | 14 (26) | 14 (26) | 17 (31) | 19 (36) | 0.64 |
| Captopril group (%) | 108 (50) | 28 (52) | 19 (36) | 31 (57) | 30 (57) | 0.093 |
| Median (IQR) days in trial | 1023 (963–1094) | 1024 (976–1103) | 1036 (991–1095) | 1027 (995–1091) | 995 (87–1097) | <0.001 |
| Median (IQR) BNP (pmol/l) | 109 (60–177) | 63 (45–102) | 103 (54–134) | 121 (69–165) | 191 (113–278) | <0.001 |
| Median (IQR) NT- proBNP (pmol/l) | 1228 (754–1978) | 714 (499–1087) | 1200 (678–1604) | 1338 (906–2039) | 2085 (1457–2476) | <0.001 |
| Mean (±SD) BMI | 26 (4) | 26 (3) | 26 (4) | 26 (4) | 26 (4) | 0.84 |
| Smokers (%) | 84 (39) | 23 (43) | 29 (55) | 15 (28) | 17 (32) | 0.021 |
| Killip class >1 (%) | 175 (82) | 37 (69) | 41 (77) | 49 (91) | 48 (91) | 0.005 |
| History of AMI (%) | 24 (11) | 4 (7) | 3 (6) | 8 (15) | 9 (17) | 0.18 |
| Diabetes (%) | 25 (12) | 6 (11) | 4 (8) | 8 (15) | 7 (13) | 0.68 |
| Hypertension (%) | 65 (30) | 13 (24) | 10 (19) | 21 (39) | 21 (40) | 0.04 |
| AF (%) | 28 (13) | 2 (4) | 4 (8) | 11 (20) | 11 (21) | 0.012 |
| Mean (±SD) SBP | 124 (17) | 123 (16) | 127 (15) | 125 (20) | 122 (18) | 0.51 |
| Mean (±SD) DBP | 68 (11) | 71 (11) | 70 (11) | 68 (10) | 64 (11) | 0.001 |
| Mean (±SD) eGFR (ml/mol/1.73 m2) | 72 (17) | 83 (12) | 80 (15) | 72 (12) | 56 (15) | <0.001 |
| Mean (±SD) creat | 93 (23) | 82 (10) | 85 (14) | 91 (16) | 114 (31) | <0.001 |
| Mean (±SD) LDLc | 3.6 (1.1) | 3.8 (1.1) | 3.4 (1.2) | 3.5 (1.0) | 3.4 (1.1) | 0.25 |
| Treatment (n (% use)) | ||||||
| β Blockers (%) | 162 (76) | 48 (89) | 41 (77) | 39 (72) | 34 (64) | 0.025 |
| Loop diuretics (%) | 159 (74) | 31 (57) | 36 (68) | 44 (81) | 48 (91) | <0.001 |
| Statins (%) | 137 (64) | 40 (74) | 37 (70) | 36 (67) | 24 (45) | 0.01 |
| Thrombolysis (%) | 129 (60) | 42 (78) | 29 (55) | 32 (59) | 26 (49) | 0.015 |
AF, atrial fibrillation; AMI, acute myocardial infarction; BMI, body mass index; BNP, B-type natriuretic peptide; chol, cholesterol; creat, creatinine; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LDLc, LDL-cholesterol; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure.